����VR��Ƶ

����VR��Ƶ is providing US$850,000 for the development of 20Med's bioresponsive polymeric nanoparticle technology, which could help end the need for frozen storage of mRNA vaccines. This funding will be used to advance a proof-of-concept for 20Med's nanoparticle platform, as well as for preclinical studies to assess whether the technology can deliver mRNA vaccines as effectively as the currently approved technology used for mRNA delivery, known as lipid nanoparticles.

����VR��Ƶ is providing up to US$2.87 million to ACM Biolabs for preclinical proof of concept of its mRNA delivery technology—the ACM Tunable Platform (“ATP”). ATP is a thermostable mRNA delivery vehicle that allows for mRNA storage at 2-8°C, in contrast to most existing mRNA delivery systems, which require ultra-low temperatures for storage.

The project will use Rabies as a model pathogen.

����VR��Ƶ is providing up to US$1.6 million to establish proof-of-concept for aVaxziPen's vaccine-delivery technology by evaluating stability, delivery and preclinical immunogenicity of both mRNA and protein-based vaccines developed using aVaxziPen's platform.

aVaxziPen's solid-dose vaccine technology uses a pen applicator device and is designed to address access challenges associated with cold-chain storage requirements by protecting the mRNA and proteins against degradation, potentially removing the need for frozen storage for mRNA vaccines and the need for cold-chain storage altogether for protein-based vaccines.

����VR��Ƶ supported the development of a vaccine candidate based on Affinivax’s innovative Multiple Antigen Presenting System (MAPSTM) technology.

The programme aimed to establish preclinical proof of concept for a vaccine candidate designed to protect against new COVID-19 variants suitable for use in the Global South.

����VR��Ƶ funding has been discontinued.

����VR��Ƶ is providing $6.2 million to researchers at Afrigen who will work with @International Vaccine Institute (IVI) to progress the new vaccine candidate through preclinical development and into Phase I clinical testing in people in either South Africa or another outbreak-affected country on the continent.

The new Afrigen vaccine candidate could help combat this threat through leveraging the cutting-edge mRNA technology developed by the company in its role as the Hub for the WHO and MPP mRNA Technology Transfer Programme which aims to build mRNA vaccine development and production capacity in low- and middle-income countries and closer to where outbreaks happen. The early discovery work by Afrigen on this vaccine candidate was funded by the ELMA Foundation.

Afrigen is committed to the potential development of investigational stockpiles for use in outbreaks, an affordable pricing mechanism for the vaccine, and endeavouring to manufacture the vaccine close to where outbreaks may occur.